Clinical trials: Metabolism Disorder
Vitamin D Deficiency, HIV
Vitamin D in HIV-Infected Patients on HAART
This is a research study to look at vitamin D deficiency (low levels) in men and women with HIV. As part of your regular medical care, you will be screened for vitamin D deficiency.
- Trial name
- NCT01250899
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of California, Los Angeles
Overweight, Autism Spectrum Disorder
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
The purpose of this study is to determine whether metformin is safe and effective in the treatment of weight or weight gain in young people with Autism Spectrum Disorders (ASD) who are currently taking atypical antipsychotic…
- Trial name
- MET (NCT01825798)
- Testing
- Metformin
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
Preventive Health Services, Health Communication
Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention
This study examines whether a health message that includes a self-affirmation intervention (where people reflect on values that are important to them) increases acceptance of the message and encourages people to take steps to…
- Trial name
- PEP (NCT03550066)
- Testing
- Values affirmation, No affirmation
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Healthy, Obese
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that…
- Conditions
- Healthy, Obese, Overweight
- Trial name
- NCT06186622
- Testing
- Orforglipron, Simvastatin, Digoxin
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type I Diabetes
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)
- Trial name
- NCT01928329
- Testing
- Exenatide (Bydureon®)
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Yale University
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Osteoarthritis, Post-traumatic Osteoarthritis
Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints.
- Trial name
- NCT04589611
- Testing
- amobarbital/Gel-One (one dose), amobarbital/Gel-One (two doses)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- J L Marsh
X-linked Adrenoleukodystrophy
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
The purpose is to see how X-linked adrenoleukodystrophy (X-ALD) is associated with strength and sensation using MRI, in women with X-ALD.
- Trial name
- NCT01594853
- Testing
- exercise training
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Pre-diabetes, Breast Cancer
Time Restricted Eating on Cancer Risk
Participants will be randomly assigned to either the time restricted feeding group with a daily eating period of 8 hours or the control group with a daily eating period of greater than or equal to 12 hours.
- Conditions
- Pre-diabetes, Breast Cancer, Time Restricted Feeding
- Trial name
- TREC (NCT05038137)
- Testing
- Time restricted feeding, Control
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Medical University of South Carolina
Diabetes Mellitus, Type 2
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial…
- Trial name
- NCT00916357
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Halozyme Therapeutics
Prader-Willi Syndrome
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
This is a multicenter, open label, multi cohort study to evaluate the efficacy and safety of somatropin in a cohort of Japanese participants with PWS.
- Trial name
- NCT04697381
- Testing
- somatropin - GH naïve pediatric cohort, somatropin - GH treated cohort, somatropin - adult cohort
- Where
- 5 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus.
- Trial name
- 1928 (NCT00659711)
- Testing
- Januvia (Sitagliptin) 100 mg
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type I
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant.
- Trial name
- NCT00888628
- Testing
- Purified Pancreatic Islets, Etanercept
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Gout
Food Effect Study of Febuxostat XR in Healthy Participants
The purpose of this study is to assess the effect of food on the bioavailability of febuxostat after a single oral dose of 80 mg febuxostat XR and to evaluate the pharmacokinetics (PK) of febuxostat after single oral doses of 40…
- Trial name
- NCT02374164
- Testing
- Febuxostat XR
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in…
- Trial name
- NCT01275131
- Testing
- Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Type 1 Diabetes, Hyperglycemia, Postprandial
Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9…
- Trial name
- NCT04079881
- Testing
- Insulin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes Mellitus
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with…
- Trial name
- NCT00571519
- Testing
- Rivoglitazone HCl, pioglitazone HCl, pioglitazone HCl 45 mg
- Where
- 18 sites in United States
- Volunteers
- 94 people
- Sponsor
- Daiichi Sankyo
Critical Illness
LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness
The LOGIC-Insulin computerized software algorithm will be compared with a nurse-directed protocol, both targeting a blood glucose level of 80-110 mg/dL, in critically ill patients
- Trial name
- LOGIC-1 (NCT01420302)
- Testing
- Nurse directed, LOGIC-Insulin
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Greet Van den Berghe
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.